Editor–The review of empagliflozin for patients with heart failure and preserved ejection
fraction (HFpEF) signals an important recognition that the management of HFpEF required a …

Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) demonstrated
a reduction in cardiovascular death or heart failure (HF) hospitalization in patients with HF …

To the Editor: Anker et al.(Oct. 14 issue) 1 report that in EMPEROR-Preserved (Empagliflozin
Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) …

The importance of HFwith preserved ejection fraction (HFpEF) as a large subtype of HF has
been recognized since the late 1980s. The quest for therapies that will reduce symptoms …

Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF) | Drug and
Therapeutics Bulletin Skip to main content Viewing from: Google Indexer BMJ Journals Subscribe …

Empagliflozin improved health–related quality of life among patients with heart failure with
preserved ejection fraction (HFpEF), showing similar results as an earlier trial of patients …

The treatment of heart failure with reduced ejection fraction (HFrEF) has been improving by
numerous pharmacological and non-pharmacological options, as described in national and …

Because of its safe, effective, and less expensive glucose-lowering effect, metformin has
long been the fundamental drug for managing type 2 diabetes mellitus (T2DM). However, in …

A subgroup analysis of the EMPEROR-Preserved trial investigated whether the benefit of
empagliflozin seen in heart failure (HF) patients with an ejection fraction (EF)> 40 …

Rates of hospitalization among patients with heart failure (HF) remain high and are a
prominent target for quality improvement. Although several therapies for HF with reduced …